$PTIX News
Last published 2d ago
- 2d agoPTIXProtagenic Therapeutics Announces Private Placement of Up to $5 Million to Advance PT00114 into Its First U.S. Clinical Trial in Generalized Anxiety DisorderACCESS NewswireProtagenic Therapeutics, Inc. (OTCQB:PTIX) ("Protagenic" or the "Company"), a clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for stress-related neuropsychiatric disorders, today announced a private placement with new and existing investors that provides $1.5 million in upfront gross proceeds. Up to $3.5 million in additional gross proceeds may be received if t ...
- 11mo agoPTIXResults from Phase 1 Multiple-Dose Study of PT00114ACCESS NewswireFindings support advancement into Phase 2 to explore a first-in-class pathway aimed at stress-related neuropsychiatric conditions NEW YORK CITY, NEW YORK / ACCESS Newswire / December 9, 2025 / Protagenic Therapeutics
- 11mo agoPTGXPTIXProtagenic Therapeutics Announces Receipt of Nasdaq Non-Compliance NoticeACCESS NewswireNEW YORK, NY / ACCESS Newswire / November 27, 2025 / Protagenic Therapeutics, Inc. today announced that it has received a notification letter from the Nasdaq Listing Qualifications
- 1y agoPTIXProtagenic Therapeutics Announces Completion of Enrollment and Dosing in Phase 1 MAD StudyACCESS NewswireNEW YORK CITY, NY / ACCESS Newswire / November 13, 2025 / Protagenic Therapeutics Inc. , a biopharmaceutical company developing novel therapeutics for stress-related neuropsychiatric and neurodegenerative
- 1y agoPTIXProtagenic Therapeutics Provides Update on Form 10-Q Filing Timeline and Nasdaq ComplianceACCESS NewswireDelay Attributable to Merger-Related Financial Consolidation NEW YORK, NY / ACCESS Newswire / August 22, 2025 / Protagenic Therapeutics, Inc. , a biopharmaceutical company developing novel neuro-active
- 1y agoPTIXProtagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood DisordersACCESS NewswireDosing Completion Expected by End of August; Phase 2 Trial Expected to Begin in 1Q 2026 NEW YORK, NY / ACCESS Newswire / August 21, 2025 / Protagenic Therapeutics, Inc. , a biopharmaceutical company
- 1y agoPTIXProtagenic Therapeutics Announces Grant of new patent in Japan for its Modified Stilbenoid Program Drug CandidatesGlobeNewswireNEW YORK and SANTA BARBARA, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) (the "Company") today announces that on July 18, 2025, the Japanese Patent Office granted Patent JP
- 1y agoPTIXProtagenic Therapeutics Receives $3.1 Million from Recent Warrant ActivityACCESS NewswireNEW YORK, NY / ACCESS Newswire / May 21, 2025 / Protagenic Therapeutics, Inc. announced today that warrant exchanges and exercises over the last four trading days have generated
- 1y agoPTIXProtagenic Therapeutics and Phytanix Announce Business Combination to form Neuroactive Biopharmaceutical Company with Six Drug Candidates in Development including Treatments for Obesity and Metabolic DisordersACCESS NewswireNEW YORK, NY AND SANTA BARBARA, CA / ACCESS Newswire / May 19, 2025 / Protagenic Therapeutics, Inc. and Phytanix Bio Inc. have entered into a definitive share exchange agreement
- 1y agoPTIXProtagenic Therapeutics to Effect 1-for-14 Reverse Stock SplitACCESS NewswireMeasure taken to Comply with Nasdaq Rule 5550 Regarding Minimum Bid Price NEW YORK, NY / ACCESS Newswire / April 29, 2025 / Protagenic Therapeutics, Inc. ("Protagenic Therapeutics" or the
- 2y agoPTIXProtagenic Therapeutics Announces Closing of Private Placement for Aggregate Gross Proceeds of $1.275 MillionACCESS NewswireNEW YORK, NY / ACCESSWIRE / November 5, 2024 / Protagenic Therapeutics, Inc. , a leader in biopharmaceutical innovation, announced today that
- 2y agoPTGXPTIXProtagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 MillionACCESS NewswireNEW YORK, NY / ACCESSWIRE / October 29, 2024 / Protagenic Therapeutics, Inc. , a leader in biopharmaceutical innovation, announced today it
- 2y agoPTIXProtagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric DisordersACCESS NewswireNo Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to CommenceInvestor Call Scheduled for today, Wednesday, May 22, at 10:00 am ET to Discuss Potential Impact on PTSD,
- 2y agoPTIXProtagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder TrialACCESS NewswireNEW YORK, NY / ACCESSWIRE / May 1, 2024 / Protagenic Therapeutics, Inc. , a leader in biopharmaceutical innovation, today announced the completion of enrollment in the single dose portion of its Phase 1
- 2y agoPTIXProtagenic Therapeutics' Innovative Peptide PT00114 to be Highlighted at Boston SummitACCESS NewswireChief Operating Officer to Present Key Advances at Peptide Therapeutics Summit NEW YORK, NY / ACCESSWIRE / April 17, 2024 / Protagenic Therapeutics, Inc. , a pioneer in biopharmaceutical research, announced
- 2y agoPTIXProtagenic Therapeutics, Inc. (PTIX) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoPTIXProtagenic Therapeutics Successfully Concludes Third Cohort in Single Dose Portion of Phase 1 Trial for Stress-Related Neuropsychiatric DisordersACCESS NewswireNext clinical progress update expected in April 2024NEW YORK, NY / ACCESSWIRE / March 27, 2024 / Protagenic Therapeutics, Inc. , a leader in biopharmaceutical innovation, advances its mission to develop
- 2y agoPTIXProtagenic Therapeutics Schedules First Q4 and FY 2023 Earnings CallACCESS NewswireCall Scheduled for Monday, April 1st, 2024, at 4:30 pm ETNEW YORK, NY / ACCESSWIRE / March 25, 2024 / Protagenic Therapeutics, Inc. , a biopharmaceutical innovator, announced that the Company plans to hold
- 2y agoPTIXProtagenic Therapeutics Announces Resolution of Nasdaq Deficiency NoticeACCESS NewswireNEW YORK, NY / ACCESSWIRE / March 21, 2024 / Protagenic Therapeutics, Inc. , a biopharmaceutical innovator, regained compliance with Nasdaq Listing Rule 5550 as the closing bid price of shares of PTIX
- 2y agoPTIXProtagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related DisordersACCESS NewswireCompany Anticipates Reporting Complete Phase I Single Dose Results in AprilNEW YORK, NY / ACCESSWIRE / February 13, 2024 / Protagenic Therapeutics, Inc. , a biopharmaceutical innovator, announced a step
- 2y agoPTIXProtagonist Reports 2-Year Follow Up Data from Rusfertide REVIVE Study at the ASH Annual Meeting Showing Durable Efficacy and No New Safety SignalsACCESS NewswireLong term follow-up from REVIVE Phase 2 study shows durable hematocrit control, decreased phlebotomy use, long-term tolerability, and no new safety signals in patients with polycythemia veraAnalysis of PACIFIC Phase 2
- 3y agoPTIXProtagenic Therapeutics Announces Date of Annual Shareholder MeetingACCESS NewswireNEW YORK, NY / ACCESSWIRE / October 13, 2023 / Protagenic Therapeutics, Inc. a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced its FY
- 3y agoPTIXProtagenic Therapeutics Initiates Phase I/IIa Clinical Trial for Groundbreaking Brain Peptide PT00114ACCESS NewswireA potential major step toward treating stress-related neuro-psychiatric disordersNEW YORK, NY / ACCESSWIRE / September 26, 2023 / Today, Protagenic Therapeutics, Inc. , a pioneering biopharmaceutical
- 4y agoPTIXProtagenic Therapeutics to Present at the B. Riley Securities Neuro and Ophthalmology Virtual Investor Conference on April 27thACCESS NewswireNEW YORK, NY / ACCESSWIRE / April 26, 2022 / Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing drug product candidates to treat stress-related neurologic disorders, today announced will be presenting at the B.
- 4y agoPTIXPTIXWProtagenic Therapeutics Announces Third Quarter 2021 Results and Business UpdateGlobeNewswireNEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced results for the third quarter ended Septem
- 5y agoPTIXPTIXWProtagenic Therapeutics to Host Virtual Science Review Wednesday, September 8th at 10 AM ETGlobeNewswireScientific rationale and evidence for PT00114 in the treatment of Depression, Anxiety, PTSD and Addiction to be discussed NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company f
- 5y agoPTIXPTIXWProtagenic Therapeutics Announces Second Quarter 2021 Results and Provides Business UpdateGlobeNewswireNEW YORK, Aug. 17, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced results for the second quarter ended June
- 5y agoPTIXPTIXWProtagenic Therapeutics Updates Timeline for Commencement of Patient Enrollment for PT00114 Clinical TrialGlobeNewswireNEW YORK, July 23, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that upon reviewing its investigational ne
- 5y agoPTIXPTIXWProtagenic Therapeutics to Host Webinar with Dr. Maurizio Fava for its Lead Molecule PT00114 on Tuesday, July 13th at 10:00 AM ETGlobeNewswireNEW YORK, July 06, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a biopharmaceutical company focused on developing therapies to treat stress-related neurologic disorders, today announced that it will host a key opinion leader (KO
- 5y agoPTIXProtagenic Therapeutics to Present at the H.C. Wainwright Psychedelics in Psychiatry and Beyond Virtual Conference on June 17thGlobeNewswireNEW YORK , June 16, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) a bioharmaceutical company focused on developing drug product candidates to treat stress-related neurologic disorders, today announced will be presenting at the H.
- 5y agoPTIXPTIXWProtagenic Therapeutics, Inc. Announces Closing of $13.2 Million Public Offering and Uplisting to NasdaqGlobeNewswireNew York, April 29, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the closing of an underwritten public offering of 3,180,000 units at a public offering price of $4.15 per unit. Each unit is
- 5y agoPTIXProtagenic Therapeutics, Inc. Announces Nasdaq Uplisting and Pricing of $13.2 Million Public OfferingGlobeNewswireNew York, April 26, 2021 (GLOBE NEWSWIRE) -- Protagenic Therapeutics, Inc. (NASDAQ:PTIX) ("PTIX" or "Company") today announced the pricing of an underwritten public offering of 3,180,000 units at a public offering price of $4.15 per unit for aggregate